am a practising community family physician with 199 patients over the age of 64 years. Eleven (5.5%) of them are taking warfarin for atrial fibrillation. Anticoagulation reduces the relative risk of stroke by about 70% over 5 years; 1 however, patients are at risk of bleeding. Although the risk of a serious life-threatening or fatal bleed is about 5% over 5 years for most patients, it is 17% over 5 years for patients over the age of 80.
I
am a practising community family physician with 199 patients over the age of 64 years. Eleven (5.5%) of them are taking warfarin for atrial fibrillation. Anticoagulation reduces the relative risk of stroke by about 70% over 5 years; 1 however, patients are at risk of bleeding. Although the risk of a serious life-threatening or fatal bleed is about 5% over 5 years for most patients, it is 17% over 5 years for patients over the age of 80. 2 Six of my patients using warfarin for atrial fibrillation are over the age of 80. I calculated their 5-year risk of having a stroke (using the Framingham calculator, www.statcoder.com) to be 18%, 19%, 21%, 31%, 41% and 55% respectively. I determined that, if a patient has a risk of stroke of 24% over 5 years, then that risk would fall by 70% with warfarin, to 7.2%. The net improvement or absolute risk reduction would be 16.8%. If the risk of a serious bleed from warfarin therapy is 17% over 5 years, then all patients with a stroke risk of 24% or less would have the benefit of warfarin therapy counterbalanced by a risk of a serious side effect. (Note that by using general principles of risk equivalence, 3 this determination can also be calculated as risk of adverse event ÷ relative risk benefit -in this case 17% ÷ 0.7 = 24%.) I reviewed the treatment of my 6 patients, and it appeared to me that 3 of them should continue to take warfarin and 3 should consider switching to ASA.
I acknowledge limitations to my approach. 
What's your opinion?
We invite you to submit your ideas about the author's approach to risk equivalence by sending an eLetter response to this article at www.cmaj.ca. The best comments will be summarized in an upcoming issue and a small prize awarded.
Do you have a case that you can't diagnose? Send a description of it to the attention of Dr. Wooltorton at eric.wooltorton@cma.ca. W e received a number of eletters (available with the original article 1 at www.cmaj.ca) suggesting possible diagnoses in the case of a man who was noted at autopsy to have several unusual structures near his pancreas. Many different pathologies were proposed, including a neuroendocrine neoplasm, cystadenoma, inflammatory pseudotumour, sclerosing mesenteritis (panniculitis), thymus remnant, tuberculoma, hamartoma, and dermoid or hydatid cysts due to foreign body reactions possibly from a remote gun-shot injury or bomb splinter.
The most common, and perhaps best argued, diagnosis was a lymphoepithelial cyst of the pancreas. Such a lesion, which is a frequent incidental finding on abdominal CT scans, is benign and occurs more commonly in men than in women. Histologically similar lesions have been found in the parotid and thyroid glands, the neck (brachial cleft cysts), the thymus and the lungs. This clinical entity was described nearly 160 years ago by a dentist who felt that the lesion's characteristic luminal pearls very closely resembled teeth. 2 The diagnosis of lymphoepithelial cyst of the pancreas reached us independently on the same day from Dr. Nick G.
van der Westhuizen and Dr. Heike Varnholt (who also pointed us to the first case report 2 ). To both we offer a small but nifty prize, a CMAJ combination pedometer and radio.
